Prevalence of multidrug-resistant Staphylococcus aureus in diabetics clinical samples
| Autor: | Shripad A. Patil, R. Kelmani Chandrakanth, Ajay Kumar Oli, Sree Bhushan Raju |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Meticillin
Physiology Teicoplanin business.industry Aminoglycoside General Medicine biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease_cause Applied Microbiology and Biotechnology Methicillin-resistant Staphylococcus aureus Virology Microbiology Penicillin Antibiotic resistance Staphylococcus aureus medicine Vancomycin business Biotechnology medicine.drug |
| Zdroj: | World Journal of Microbiology and Biotechnology. 26:171-176 |
| ISSN: | 1573-0972 0959-3993 |
| DOI: | 10.1007/s11274-009-0157-5 |
| Popis: | Antibiotic resistance in 40 Staphylococcus aureus clinical isolates from 110 diabetic patients (36%) was evaluated. Of these, 32 (80%) of the isolates showed multidrug-resistance to more than eight antibiotics and 35% isolates were found to be methicillin resistant S. aureus (MRSA). All 40 S. aureus strains (100%) screened from diabetic clinical specimens were resistant to penicillin, 63% to ampicillin, 55% to streptomycin, 50% to tetracycline and 50% to gentamicin. Where as low resistance rate was observed to ciprofloxacin (20%) and rifampicin (8%). In contrast, all (100%) S. aureus strains recorded susceptibility to teicoplanin, which was followed by vancomycin (95%). Genotypical examination revealed that 80% of the aminoglycoside resistant S. aureus (ARSA) have aminoglycoside modifying enzyme (AME) coding genes; however, 20% of ARSA which showed non-AME mediated (adaptive) aminoglycoside resistance lacked these genes in their genome. In contrast all MRSA isolates possessed mecA, femA genetic determinants in their genome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink